Advertisement

International Journal of Hematology

, Volume 73, Issue 2, pp 213–221 | Cite as

Re-Treatment of Relapsed Indolent B-Cell Lymphoma With Rituximab

  • Tadahiko Igarashi
  • Tomoko Ohtsu
  • Hirofumi Fujii
  • Yasutsuna Sasaki
  • Yasuo Morishima
  • Michinori Ogura
  • Yoshitoyo Kagami
  • Tomohiro Kinoshita
  • Masaharu Kasai
  • Yoshio Kiyama
  • Yukio Kobayashi
  • Kensei Tobinai
  • Members of the IDEC-C2B8 Study Group
Case Report

Abstract

The purpose of this study was to investigate the toxicity and the efficacy of re-treatment with rituximab, a chimeric mouse human anti-CD20 monoclonal antibody, in relapsed patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) who responded to rituximab in the previous phase I or phase II study. Thirteen patients with relapsed B-cell NHL, each of whom was confirmed to have Revised European-American Lymphoma Classification type II, 1–6 histology (indolent B-NHL), enrolled in this re-treatment study. All were re-treated with rituximab at 375 mg/m2 weekly for 4 consecutive weeks. Rituximab re-treatment was well tolerated with no grade 3/4 nonhematological toxicities, similar to that of the initial treatment. No patients developed detectable human anti-chimeric antibody. Partial responses were observed in 5 of 13 patients (38%; 95% confidence interval [CI], 14% to 68%); 6 patients showed stable disease and 2 showed progressive disease. Overall survival rate was 93% at 19 months of median follow-up after rituximab re-treatment. Median progression-free survival (PFS) after the re-treatment was 5.1 months (95% CI, 4.1 to 5.6 months), and the median PFS after the initial treatment was 8.2 months (95%CI, 5.9 to 11.3 months). Although rituximab re-treatment induced prolonged depletion of normal peripheral blood B cells in all patients, no significant decrease in serum immunoglobulin or complement level was observed. In conclusion, rituximab re-treatment was well tolerated, and it may produce a prolonged PFS in some patients with indolent B-cell NHL who showed initial response to rituximab.

Key words

Rituximab Monoclonal antibody Re-treatment Indolent B-cell lymphoma CD20 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Reff ME, Carner K, Chambers KS, et al. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20.Blood. 1994;83:435–445.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.Blood. 1994;84:2457–2466.PubMedGoogle Scholar
  3. 3.
    Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma.Blood. 1997;90:2188–2195.PubMedGoogle Scholar
  4. 4.
    McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol. 1998;16:2825–2833.CrossRefPubMedGoogle Scholar
  5. 5.
    Tobinai K, Kobayashi Y, Narabayashi M, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma.Ann Oncol. 1998;9:527–534.CrossRefPubMedGoogle Scholar
  6. 6.
    Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.Blood. 1998;92:1927–1932.PubMedGoogle Scholar
  7. 7.
    Davis TA, White CA, Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab.J Clin Oncol. 1999;17:1851–1857.CrossRefPubMedGoogle Scholar
  8. 8.
    Tobinai K, Kobayashi Y, Ohtsu T, et al. Phase II study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed indolent B-cell lymphoma [abstract].Ann Oncol. 1999;10(suppl 3):133.Google Scholar
  9. 9.
    Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.Blood. 1994;84:1361–1392.PubMedGoogle Scholar
  10. 10.
    Oken MM, Creech RH, Tormey DC, Horton J. Toxicity and response criteria of Eastern Cooperative Oncology Group.Am J Clin Oncol. 1982:5;649–655.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group.Jpn J Clin Oncol. 1993;23:250–257.CrossRefPubMedGoogle Scholar
  12. 12.
    Grillo-Lopez AJ, Cheson BD, Horning SJ, et al. Response criteria for NHL: importance of “normal” lymph node size and correlations with response rate.Ann Oncol. 2000;11:399–408.CrossRefPubMedGoogle Scholar
  13. 13.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.J Am Stat Assoc. 1958;53:457–481.CrossRefGoogle Scholar
  14. 14.
    Mantel L. Evaluation of survival data and two new rank order statistics arising in its consideration.Cancer Chemother Rep. 1966;50:163–170.PubMedGoogle Scholar
  15. 15.
    The International Non-Hodgkin’s Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin’s lymphoma.N Engl J Med. 1993;329:987–994.CrossRefGoogle Scholar
  16. 16.
    Lopez-Guillermo A, Montserrat E, Boche F, et al. Applicability of the international index for aggressive lymphomas to patients with low-grade lymphoma.J Clin Oncol. 1994;12:1343–1348.CrossRefPubMedGoogle Scholar
  17. 17.
    Hermans J, Krol ADG, van Groningen K, et al. International prognostic index for aggressive non-Hodgkin’s lymphoma is valid for all malignancy grades.Blood. 1995;86:1460–1463.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Davis T, Levy R, White CA, et al. Rituximab: phase II retreatment study in patients with low-grade or follicular NHL [abstract].Blood. 1998;15(suppl 1):414a.Google Scholar
  19. 19.
    McLaughlin P, Grillo-Lopez AJ, White C, et al. Prognostic factors for non-Hodgkin’s lymphoma patients treated may not predict response duration in patients treated with immunotherapy: rituximab experience [abstract].Proc Am Assoc Cancer Res. 1999;40:718.Google Scholar
  20. 20.
    Schmitz K, Brugger W, Weiss B, Kaiserling E, Kanz L. Clonal selection of CD20-negative non-Hodgkin’s lymphoma cells after treatment with anti-CD20 antibody rituximab [letter].Br J Haematol. 1999;106:571–572.CrossRefPubMedGoogle Scholar
  21. 21.
    Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.Clin Cancer Res. 1999;5:611–615.PubMedGoogle Scholar
  22. 22.
    Micallef IN, Kirk A, Norton A, Foran JM, Rohatiner AZ, Lister TA. Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma [letter].Blood. 1999;93:2427–2428.PubMedGoogle Scholar
  23. 23.
    Kinoshita T, Nagai H, Murate T, Saito H. CD20-negative relapse in B-cell lymphoma after treatment with rituximab [letter].J Clin Oncol. 1998;16:3916.CrossRefPubMedGoogle Scholar
  24. 24.
    Foran JM, Rohatiner AZS, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.J Clin Oncol. 2000;18:317–324.CrossRefPubMedGoogle Scholar
  25. 25.
    Foran JM, Cunningham D, Coiffier B, et al. Treatment of mantle-cell lymphoma with rituximab (chimeric anti-CD20 monoclonal antibody): analysis of factors associated with response.Ann Oncol. 2000;11(suppl 1):117–121.CrossRefPubMedGoogle Scholar
  26. 26.
    Ogura M, Igarashi T, Morishima Y, et al. Factors affecting toxicity, response and time to progression in relapsed patients with indolent B-NHL and mantle cell lymphoma treated with rituximab [abstract].Proc Am Soc Clin Oncol. 2000;19:25.Google Scholar
  27. 27.
    Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma.Ann Oncol. 1999;10:655–661.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2001

Authors and Affiliations

  • Tadahiko Igarashi
    • 1
  • Tomoko Ohtsu
    • 1
  • Hirofumi Fujii
    • 1
  • Yasutsuna Sasaki
    • 1
  • Yasuo Morishima
    • 2
  • Michinori Ogura
    • 2
  • Yoshitoyo Kagami
    • 2
  • Tomohiro Kinoshita
    • 3
  • Masaharu Kasai
    • 4
  • Yoshio Kiyama
    • 4
  • Yukio Kobayashi
    • 5
  • Kensei Tobinai
    • 5
  • Members of the IDEC-C2B8 Study Group
  1. 1.Hematology and OncologyNational Cancer Center Hospital EastKashiwa
  2. 2.Department of Hematology and ChemotherapyAichi Cancer CenterNagoya
  3. 3.Department of Internal MedicineNagoya University School of MedicineNagoya
  4. 4.Department of Internal MedicineSapporo Hokuyu HospitalSapporo
  5. 5.Hematology DivisionNational Cancer Center HospitalTokyoJapan

Personalised recommendations